A statement released earlier today by BNP PARIBAS about Bayer (ETR:BAYN) ups the target price to 103.00EUR
- Updated: October 2, 2016
Indicating a possible upside of 0.15%, BNP PARIBAS bumped up the target of Bayer (ETR:BAYN) to 103.00EUR
Previously on Sunday October 02, 2016, BNP PARIBAS reported about Bayer (ETR:BAYN) raised the target price from 0.00EUR to 103.00EUR. At the time, this indicated a possible upside of 0.15%.
Yesterday Bayer (ETR:BAYN) traded 0.00% even at 89.38EUR. The company’s 50-day moving average is 0.04EUR and its 200-day moving average is 0.03EUR. The last stock close price is up -4.07% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 215
See Chart Below
Bayer has a one year low of 0.03EUR and a one year high of 0.04EUR Bayer’s market capitalization is currently 0 EUR.
Brief Synopsis On Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.